Andreas L. Marzinzik

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Safe and Reliable Synthesis of Diazoketones and Quinoxalines in a Continuous Flow Reactor

Laetitia J. Martin, Andreas L. Marzinzik, Steven V. Ley et al. · Organic Letters · 2010 · 133 citations · Full text

Aromatic Diazoketones, Engineering, Organic Chemistry +16

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Wolfgang Jahnke, Robert M. Grotzfeld, Xavier Pellé et al. · Journal of the American Chemical Society · 2010 · 124 citations

Drug Target, Molecular Biology, Allosteric Inhibitors +16

Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery

Wolfgang Jahnke, Jean‐Michel Rondeau, Simona Cotesta et al. · Nature Chemical Biology · 2010 · 121 citations · Full text

Medicinal Chemistry, Drug Target, Medicine +5